General Information of the Protein
| Protein ID |
PT02921
|
||||
|---|---|---|---|---|---|
| Protein Name |
Corticotropin-releasing factor receptor 2
|
||||
| Secondarily Protein Name |
Corticotropin-releasing hormone receptor 2
|
||||
| Gene Name |
CRHR2
|
||||
| Secondarily Gene Name |
CRF2R
CRH2R
|
||||
| Sequence |
MDAALLHSLLEANCSLALAEELLLDGWGPPLDPEGPYSYCNTTLDQIGTCWPRSAAGALVERPCPEYFNGVKYNTTRNAYRECLENGTWASKINYSQCEPILDDKQRKYDLHYRIALVVNYLGHCVSVAALVAAFLLFLALRSIRCLRNVIHWNLITTFILRNVMWFLLQLVDHEVHESNEVWCRCITTIFNYFVVTNFFWMFVEGCYLHTAIVMTYSTERLRKCLFLFIGWCIPFPIIVAWAIGKLYYENEQCWFGKEPGDLVDYIYQGPIILVLLINFVFLFNIVRILMTKLRASTTSETIQYRKAVKATLVLLPLLGITYMLFFVNPGEDDLSQIMFIYFNSFLQSFQGFFVSVFYCFFNGEVRSAVRKRWHRWQDHHSLRVPMARAMSIPTSPTRISFHSIKQTAAV
Show/Hide
|
||||
| Organism |
Homo sapiens, Human
|
||||
| Protein Classification |
Membrane receptor
>
Family B G protein-coupled receptor
>
Peptide receptor (family B GPCR)
>
Corticotropin releasing factor receptor
>
Corticotropin releasing factor receptor
|
||||
| Function |
G-protein coupled receptor for CRH (corticotropin-releasing factor), UCN (urocortin), UCN2 and UCN3. Has high affinity for UCN. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and down-stream effectors, such as adenylate cyclase. Promotes the activation of adenylate cyclase, leading to increased intracellular cAMP levels.
Show/Hide
|
||||
| Uniprot ID |
Show/Hide
|
||||
| HGNC ID | |||||
| Subcellular Location |
Cell membrane
|
||||
Map of Molecular Bioactivity Related to the Protein
|
Map of Molecular Bioactivity Related to the Protein Protein Cell Line Compound Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Protein
Cell Line ID: CL000011 , CHO
Biochemical Assays
Clinical Information about the Protein
Target 1 ( Corticotropin-releasing factor receptor 2 (CRHR2) )
| Target Type | Clinical trial Target | ||||
|---|---|---|---|---|---|
| Disease | 2 Target-related Diseases | 2 | |||
| 1 | Eating disorder [ICD-11: 6B82] | ||||
| 2 | Anxiety disorder [ICD-11: 6B00-6B0Z] | ||||
| Clinical Trial Drug(s) | 1 Clinical Trial Drug | 1 | |||
| 1 | NBI-34041 | Phase 1 | |||
| Discontinued Drug(s) | 1 Discontinued Drug | 1 | |||
| 1 | SC-241 | Terminated | |||